Drugs / XT-0528
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05474859 | Dec 2024 → Jan 2028 expected | metastatic neoplasm | Xenthera, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XT-0528 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05474859 ↗ |
| Route | Oral | “continuous oral doses” NCT05474859 ↗ |